US2016331785A1PendingUtilityA1
Cells Treated by In Vitro Fucosylation and Methods of Production and Use Thereof
Est. expiryApr 18, 2023(expired)· nominal 20-yr term from priority
A61P 7/06A61P 35/02A61P 43/00A61P 7/00C12N 5/0647C12N 5/0006A61K 35/28A61K 2035/124A61P 19/00C12N 5/0634
61
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A population of cells possesses enhanced selectin binding based upon a fucosylated selectin ligand present on a surface thereof. Methods of producing the population of cells, along with therapeutic methods of using the cells, are also disclosed.
Claims
exact text as granted — not AI-modifiedWhat is claimed is:
1 . An isolated population of cells carrying on their surface a fucosylated selectin ligand, wherein the amount of fucosylated selectin ligand is sufficient to cause at least 75% of the cells in the population to bind to the selectin.
2 . The population of cells of claim 1 , wherein at least 90% of the cells in the population bind to the selectin.
3 . The population of cells of claim 1 , wherein at least 95% of the cells in the population bind to the selectin.
4 . The population of cells of claim 1 , wherein the cells are blood cells.
5 . The population of cells of claim 4 , wherein the cells are leukocytes.
6 . The population of cells of claim 1 , wherein the cells are stem cells.
8 . The population of cells of claim 1 , wherein the cells are produced by a process comprising the step of contacting the population of cells with an α1,3-fucosyltransferase in vitro in the presence of a fucose donor so as to fucosylate at least one glycoprotein on the surface of the population of cells to produce a fucosylated selectin ligand on the surface of the cells.
9 . A composition comprising:
a therapeutically effective amount of the isolated population of cells of claim 1 ; and a pharmaceutically acceptable carrier.
10 . A therapeutic method, comprising the step of:
administering the composition of claim 9 to a subject in need of a treatment involving enhanced binding of the subject's cells to the selectin.
11 . A process of producing a population of cells exhibiting enhanced binding to a selectin, the process comprising the step of:
contacting an isolated population of cells with an α1,3 fucosyltransferase and a fucose donor in vitro, wherein the cells have a glycoprotein on a surface thereof forms a selectin ligand when fucosylated, and wherein said contact results in fucosylation of the glycoprotein and thereby produces a population of fucosylated cells exhibiting enhanced binding to the selectin.
12 . The process of claim 11 , wherein the cells are blood cells.
13 . The process of claim 11 , wherein the blood cells are leukocytes.
14 . The process of claim 11 , wherein the cells are stem cells.
15 . The process of claim 11 , wherein the fucose donor is GDP-fucose.
16 . The process of claim 11 , wherein the α1,3 fucosyltransferase is α1,3-fucosyltransferase III (FTIII).
17 . The process of claim 11 , wherein the α1,3 fucosyltransferase is α1,3-fucosyltransferase IV (FTIV).
18 . The process of claim 11 , wherein the α1,3 fucosyltransferase is α1,3-fucosyltransferase V (FTV).
19 . The process of claim 11 , wherein the α1,3 fucosyltransferase is α1,3-fucosyltransferase VI (FTVI).
20 . The process of claim 11 , wherein the α1,3 fucosyltransferase is α1,3-fucosyltransferase VII (FTVII).Join the waitlist — get patent alerts
Track US2016331785A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.